Dietary Supplements

EXECUTIVE SUMMARY - Recent sources show an active, multi‑track effort to identify supplements that plausibly support healthy aging (brain, joints, metabolic health) and to move claims from anecdote to trial evidence — especially for NAD+ precursors (NR/NMN), urolithin A, omega‑3/fish oil, curcumin/turmeric, creatine, and some botanical extracts (ginkgo, thymol/carvacrol, boswellia, glucosamine/collagen). (High confidence — multiple preclinical studies, meta‑analyses, and early clinical trials.) - Two practical trends matter for a consumer or clinician: (1) brands and researchers are increasingly running controlled trials and using formal statistical/grade frameworks to support claims (Citruslabs guidance), and (2) most promising agents have strong preclinical data but only preliminary or mixed randomized‑trial evidence in humans (curcumin/weight, creatine/Alzheimer’s pilot, NR/NMN and urolithin ongoing trials). (High confidence.) - Why read the originals: they provide the primary trial results, mechanistic animal data, or regulatory/marketing caveats you need to judge whether a supplement is ready for routine use (for example, the curcumin dose‑response meta‑analysis and the small creatine RCT give opposite levels of readiness). (Actionable: check the full papers/videos before changing a regimen.) - Bottom line: some supplements show biologic plausibility and early human signals (omega‑3s, curcumin, NAD+ precursors, creatine), but most require larger randomized trials (and attention to formulation, dose, safety and validated endpoints) before being recommended as core “healthy‑aging” prescriptions. (Moderate–high confidence.)

KEY DEVELOPMENTS (max 5)

1) Growth of trial‑grade evidence and industry emphasis on rigorous claims - Summary: Industry and CROs are pushing brands to run IRB‑grade trials, use proper statistical thresholds and generate marketing‑ready endpoints (Citruslabs guides on clinical validation, statistical significance, palatability testing). This changes how supplements are marketed and evaluated. - Sources: Citruslabs — “Using Statistical Significance to Back Up Your Product Claims” (https://www.citruslabs.com/post/using-statistical-significance-to-back-up-your-product-claims); Citruslabs — “The Science Behind Ginkgo Supplements” (https://www.citruslabs.com/post/the-science-behind-ginko-supplements).

2) NAD biology & translation: strong preclinical rationale; early human work and ongoing trials - Summary: NAD+ decline is linked to aging; labs report that boosting NAD+ (NR/NMN) or reducing NAD consumption (CD38 inhibition) can improve mitochondrial / neuronal resilience. Several preclinical models and initial human studies are prompting phase‑2 trials (including brain‑targeted endpoints, urolithin A trials for Alzheimer’s). Debate remains over best target (boost supply vs inhibit consumers). - Sources: Interview/overview with Dr. Fang (NAD research and NR clinical translation) — YouTube (https://www.youtube.com/watch?v=pqKa4QbYhWg); Nature Aging commentary — “Boosting astrocytic NAD+ against tauopathy” (https://doi.org/10.1038/s43587-025-00979-y); Dr. Fang interview referencing NR/NMN work (https://www.youtube.com/watch?v=pqKa4QbYhWg).

3) Curcumin/turmeric: meta‑analysis shows modest anthropometric benefits in prediabetes/T2D but evidence certainty varies - Summary: A GRADE‑assessed dose‑response meta‑analysis of RCTs found small but statistically significant reductions in body weight and waist circumference for people with T2DM and prediabetes; certainty ranges from very low to moderate depending on outcome and heterogeneity. - Sources: Nutrition & Diabetes meta‑analysis (Moradi Baniasadi et al., 2025) (https://doi.org/10.1038/s41387-025-00386-7).

4) Cognitive/brain supplements: creatine, lithium orotate, urolithin A — early, promising but preliminary - Summary: Small RCT (n=20) reported that 20 g/day creatine for 8 weeks raised brain creatine ~11% and produced cognitive signals in Alzheimer’s patients; lithium orotate and urolithin A show striking preclinical results (mice) and are entering clinical testing — but human evidence remains early and incomplete. - Sources: Creatine trial (Modern Healthspan interview with Dr. Taylor) — YouTube (https://www.youtube.com/watch?v=yYLNHcAkeg8); Lithium orotate/Harvard summary — YouTube summary of Nature study (https://www.youtube.com/watch?v=Y9tR3l5RhhU); Urolithin A phase‑2 trial plan (Dr. Fang interview) — YouTube (https://www.youtube.com/watch?v=pqKa4QbYhWg).

5) Evidence‑based supplements for joints and circulation with mixed clinical signals - Summary: Stanford Lifestyle Medicine lists five commonly used joint supplements (glucosamine + chondroitin, curcumin, omega‑3 fish oil, collagen, Boswellia) and summarizes the variable trial support — some symptomatic benefits but heterogeneous effect sizes and populations. - Sources: Stanford — “5 Supplements for Joint Health” (https://lifestylemedicine.stanford.edu/supplements-joint-health/); Stanford newsletter (https://conta.cc/3UMYTFL#new_tab).

FACTS (verifiable statements)

• Statement: A GRADE‑assessed meta‑analysis of RCTs reported curcumin/turmeric produced an average weight reduction of −1.9 kg in people with T2D.

• Source Reference: “The effect of turmeric/curcumin supplementation on anthropometric indices…” Nutrition & Diabetes (2025) — DOI: https://doi.org/10.1038/s41387-025-00386-7 — (see pooled WMD = −1.9 kg).

• Statement: Citruslabs recommends 120–240 mg/day curcuminoid regimens (clinical trial durations cited 8–24 weeks) for trials targeting cognitive/circulatory claims for ginkgo/curcumin formulations.

• Source Reference: Citruslabs — “The Science Behind Ginkgo Supplements” (https://www.citruslabs.com/post/the-science-behind-ginko-supplements) — (design guidance: “Dosage & Duration: Effective studies often use 120–240 mg/day over 8–24 weeks.”)

• Statement: A small pilot RCT (n=20) administering 20 g/day creatine for 8 weeks in Alzheimer's patients reported an 11% increase in brain creatine (measured by MRS) and improvements in some cognitive domains.

• Source Reference: Modern Healthspan interview with Dr. Taylor summarizing the trial (https://www.youtube.com/watch?v=yYLNHcAkeg8).

• Statement: Stanford Lifestyle Medicine lists five supplements commonly discussed for joint health: glucosamine + chondroitin, curcumin, omega‑3 fish oil, collagen (hydrolyzed), and Boswellia serrata.

• Source Reference: Stanford Lifestyle Medicine — “5 Supplements for Joint Health” (https://lifestylemedicine.stanford.edu/supplements-joint-health/).

• Statement: Citruslabs and other CRO guidance emphasize that “clinically proven” claims require statistically robust RCTs and that statistical significance (p‑values), clinical relevance and trial quality (GRADE) must all be considered.

• Source Reference: Citruslabs — “Using Statistical Significance to Back Up Your Product Claims” (https://www.citruslabs.com/post/using-statistical-significance-to-back-up-your-product-claims).

OPINIONS (subjective viewpoints)

• Statement: “Metformin is being tested as an anti‑aging drug and may have benefits we still don't fully understand.”
• Author: Dr. Leslie Kernisan (geriatrician)

• Source Reference: Better Health While Aging video podcast — “Diabetes in Aging” (Dr. Kernisan) (https://www.youtube.com/watch?v=EAKd7o9MBlc) — (“[metformin] is being tested right now as an anti‑aging drug”).

• Statement: “Movement is medicine — many people are afraid of pain and stop moving, but safe activity reduces joint pain over time.”

• Author: Corey Rovzar, PhD, DPT (Stanford Lifestyle Medicine interview)

• Source Reference: Stanford Lifestyle Medicine — “Understanding ‘Good’ vs. ‘Bad’ Joint Pain” (https://lifestylemedicine.stanford.edu/good-bad-joint-pain/).

• Statement: “Brands should not rely on anecdote; clinical trials make a supplement ‘science‑backed’ and marketable.”

• Author: Citruslabs (industry viewpoint)
• Source Reference: Citruslabs — “The Science Behind Ginkgo Supplements” (https://www.citruslabs.com/post/the-science-behind-ginko-supplements) and “Using Statistical Significance…” (https://www.citruslabs.com/post/using-statistical-significance-to-back-up-your-product-claims).

DISAGREEMENTS / AREAS OF UNCERTAINTY

1) Best NAD+ strategy: boost precursors vs inhibit NAD consumers - Concept: whether the optimal translational strategy for restoring NAD+ biology is to provide precursors (NR/NMN) or to inhibit NAD‑consuming enzymes (e.g., CD38). - Source A Position: Dr. Guoqiang Fang (interview) notes strong preclinical and some clinical data for NR/NMN and sees trials ongoing; he also highlights CD38 inhibition as promising but with safety/questions about broader effects of inhibiting DNA‑repair‑linked PARPs (https://www.youtube.com/watch?v=pqKa4QbYhWg). - Source B Position: Nature Aging commentary and other researchers argue that targeting CD38 (to slow NAD+ loss) shows convincing preclinical results and may be an attractive approach (see REV‑ERBα–NFIL3–CD38 axis commentary) (https://doi.org/10.1038/s43587-025-00979-y). - Note: both approaches are active areas of research; no consensus yet.

2) Strength of evidence for fish oil / omega‑3 across indications - Concept: whether omega‑3 fish oils reliably improve joint/osteoarthritis pain. - Source A Position: Stanford notes "evidence is mixed for osteoarthritis pain; more consistent benefits appear in rheumatoid arthritis for inflammation" (https://lifestylemedicine.stanford.edu/supplements-joint-health/). - Source B Position: Citruslabs recommends fish oil claims for heart health (qualified FDA statements) and outlines evidence for cognitive/eye/anti‑inflammatory effects, but stresses careful claim substantiation (https://www.citruslabs.com/post/how-to-back-fish-oil-claims-with-research). - Takeaway: omega‑3 benefits are indication‑specific and evidence strength varies.

3) Marketing claims vs clinical reality - Concept: whether popular supplements (e.g., ginkgo for cognition, curcumin for systemic benefits) are ready for broad clinical endorsement. - Source A Position: Industry/brand guidance (Citruslabs) argues that rigorous trials are required before claims (https://www.citruslabs.com/post/the-science-behind-ginko-supplements). - Source B Position: Many clinical/population resources (Stanford, Nutrition & Diabetes meta‑analyses, YouTube researchers) report promising but mixed evidence — e.g., curcumin shows modest anthropometric effects but evidence certainty is variable (https://doi.org/10.1038/s41387-025-00386-7). - Practical implication: consumers should not assume marketed claims equal high‑certainty clinical benefit.

ADDITIONAL NOTES / SOURCES (URLs) - Better Health While Aging — Diabetes in Aging (Dr. Kernisan): https://www.youtube.com/watch?v=EAKd7o9MBlc - Better Health While Aging — Constipation, Labs, Dehydration (context on lifestyle vs meds): https://www.youtube.com/watch?v=w_Ol4q_ze6M, https://www.youtube.com/watch?v=M2cAj6IppM0, https://www.youtube.com/watch?v=OCWvaUcSPOU - Stanford Lifestyle Medicine — supplements/joint health content: https://lifestylemedicine.stanford.edu/supplements-joint-health/ and newsletter https://conta.cc/3UMYTFL#new_tab - Citruslabs — Ginkgo science: https://www.citruslabs.com/post/the-science-behind-ginko-supplements - Citruslabs — Statistical significance & product claims: https://www.citruslabs.com/post/using-statistical-significance-to-back-up-your-product-claims - Citruslabs — Fish oil claims guidance: https://www.citruslabs.com/post/how-to-back-fish-oil-claims-with-research - Curcumin meta‑analysis (Nutrition & Diabetes, 2025): https://doi.org/10.1038/s41387-025-00386-7 - Creatine small RCT summary (Modern Healthspan / Dr. Taylor interview): https://www.youtube.com/watch?v=yYLNHcAkeg8 - Dr. Fang interview (NAD, NR/NMN, urolithin): https://www.youtube.com/watch?v=pqKa4QbYhWg - Lithium orotate summary (Harvard/Nature coverage video): https://www.youtube.com/watch?v=Y9tR3l5RhhU - Urolithin A preclinical and planned phase‑2 trial notes: Dr. Fang interview (link above) - Stanford “Good vs Bad Joint Pain” (context for lifestyle and supplement role): https://lifestylemedicine.stanford.edu/good-bad-joint-pain/

CONFIDENCE GRADES (high‑level) - Preclinical mechanistic results (NAD, urolithin, thymol/carvacrol): high for animal/cellular data but translational uncertainty to humans. - Small human RCT signals (creatine pilot, some curcumin trials): preliminary/moderate — hypothesis‑generating, not definitive. - Meta‑analytic pooled effects for curcumin in T2D/prediabetes: moderate‑to‑low GRADE depending on outcome (reported in the meta‑analysis). - Regulatory/industry guidance (Citruslabs) on trials and statistical reporting: factual industry practice and strongly recommended.

WHAT TO DO NEXT (for a reader building a regimen for healthy aging) - Read the original trial or meta‑analysis before adopting a product: check dose, formulation, population, outcomes, safety (see Citruslabs guidance). - Prioritize supplements with consistent human signals and acceptable safety profiles for your goal (e.g., omega‑3 for cardiovascular risk; discuss curcumin/NR/creatine with clinicians if considering off‑label use). - Watch for larger phase‑2/3 trials (NR/NMN, urolithin A, creatine neuro trials) and independent meta‑analyses; avoid marketing hype without clinical backing.

If you want, I can: - produce a 1‑page quick‑reference table (supplement | human evidence level | typical dose/formulation | safety notes) based on these sources, or - extract the key trial citations (PMIDs/DOIs) and confidence ratings into CSV for your records. Which would you prefer?